LONDON, Dec. 2, 2016 /PRNewswire/ -- Australian medtech startup 4Dx is making a bold foray into the global respiratory diagnostics marketplace after strong support from the U.S, U.K and Australian investment community. Their AU$4M Series A investment round is set to close, oversubscribed, on December 9th after the inking of deals with major U.S hospitals and expanding relationships with key U.K medical institutions.
4Dx has developed unique software that generates moving, ultra-high-resolution images of motion and airflow in lung tissue.
This revolutionary technology enables clinicians to view and measure abnormal lung function at the earliest stages of disease in a way that has not previously been possible. 4Dx technology is non-invasive and will have a major impact on the way medical professionals are able to diagnose and treat patients with diseases of the lung.
4Dx has also established formal clinical partnerships with several of the biggest and most advanced hospitals in the US, including Cedars-Sinai, The Cleveland Clinic, Children's Hospital Los Angeles, and the University of North Carolina at Chapel Hill.
The company has also announced the appointment of Dr Bob Figlin to the 4Dx board from December 1st. Dr Figlin is Deputy Director of the Integrated Oncology Service Line, and Deputy Director at the Samuel Oschin Comprehensive Cancer Institute, part of the world-renowned Cedars-Sinai Medical Center in Los Angeles. He is also Director of the Hematology Oncology Division at the institute.
Dr Figlin says, "4Dx has developed some of the most promising and exciting technology I've ever seen in the fight against disease. It will be a privilege to be able to use my medical and business experience to assist the company through this phase of its growth." Dr Figlin previously co-founded biotechnology company Agensys, which later sold as part of a nine-figure deal.
4Dx founder and chair Andreas Fouras, says, "Dr Figlin brings unparalleled experience and expertise in cancer therapies to 4Dx, where enhanced cancer treatment is among our first priorities. He also brings a vast medical knowledge and adds enormous capacity to our board's business decision making capacity."
4Dx is using investment monies to finance further clinical studies in addition to its first FDA submission, expected in Q1 2017. The AU$4M series A is open for investment in Australia and has also received strong interest from U.S and U.K markets, and will close on the 19th December. The company anticipates the raise will be over-subscribed. An additional round of fundraising is also planned for Q1 2017.
Contact
Sarah Kemter
Monsoon Communications
+61 0407 162 530
sarahk@monsoon.com.au
About 4Dx:
4Dx is a software company aiming to deliver the global gold standard in respiratory diagnostics for all lung disorders, including, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and cancer.
The unique 4Dx technology accurately and quickly scans lung function as the patient breathes, to provide sensitive, early diagnosis and to monitor changes over time. Our Software-as-a-Service scans deliver much more complete results, showing the subtlest variations in lung function down to the finest details, using lower levels of radiation than traditional methods.
Respiratory diagnosis is a AU$40 billion p.a global industry that 4Dx aims to disrupt and grow through technology that provides clinicians with greater insights into diseases of the lung. 4Dx will bring about a step change in lung health by providing better information to doctors and patients. Better information means better decisions, and better outcomes.
